MX2021011469A - Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas. - Google Patents

Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.

Info

Publication number
MX2021011469A
MX2021011469A MX2021011469A MX2021011469A MX2021011469A MX 2021011469 A MX2021011469 A MX 2021011469A MX 2021011469 A MX2021011469 A MX 2021011469A MX 2021011469 A MX2021011469 A MX 2021011469A MX 2021011469 A MX2021011469 A MX 2021011469A
Authority
MX
Mexico
Prior art keywords
infective endocarditis
plyss2 lysin
antibiotics
sub
mic
Prior art date
Application number
MX2021011469A
Other languages
English (en)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2021011469A publication Critical patent/MX2021011469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación está dirigida a un método para tratar o prevenir la endocarditis infecciosa debida a bacterias grampositivas, como S. aureus, cuyo método incluye administrar una cantidad terapéuticamente eficaz de una combinación de uno o más antibióticos, opcionalmente por debajo del mínimo. Nivel de concentración inhibitoria (MIC) y una lisina PlySs2, como una dosis única de lisina PlySs2 a un nivel sub-MIC, en el que uno o más antibióticos y la lisina PlySs2 se administran simultánea o secuencialmente a un sujeto que lo necesite en cualquier momento. pedido.
MX2021011469A 2019-03-22 2020-03-20 Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas. MX2021011469A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962822386P 2019-03-22 2019-03-22
US201962832708P 2019-04-11 2019-04-11
US201962849093P 2019-05-16 2019-05-16
US201962898379P 2019-09-10 2019-09-10
US202062965720P 2020-01-24 2020-01-24
PCT/US2020/024051 WO2020198073A1 (en) 2019-03-22 2020-03-20 Method of treating infective endocarditis

Publications (1)

Publication Number Publication Date
MX2021011469A true MX2021011469A (es) 2021-10-22

Family

ID=72611751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011469A MX2021011469A (es) 2019-03-22 2020-03-20 Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.

Country Status (11)

Country Link
US (1) US20220160842A1 (es)
EP (1) EP3941504A4 (es)
JP (1) JP2022525914A (es)
KR (1) KR20210141667A (es)
CN (1) CN114025782A (es)
AU (1) AU2020244764A1 (es)
BR (1) BR112021018219A2 (es)
CA (1) CA3134154A1 (es)
IL (1) IL286389A (es)
MX (1) MX2021011469A (es)
WO (1) WO2020198073A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023560A1 (en) * 2021-08-17 2023-02-23 Contrafect Corporation New uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145573A2 (en) * 2011-04-21 2012-10-26 Universiteit Utrecht Holding Bv Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
CN107189997A (zh) * 2011-04-21 2017-09-22 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
EP2849782B1 (en) * 2012-05-09 2020-03-18 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
CA2872911C (en) * 2012-05-09 2023-10-03 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
BR112018005318A2 (pt) * 2015-09-17 2018-12-11 Contrafect Corporation ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
US10851401B2 (en) * 2016-05-12 2020-12-01 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
US20220023399A1 (en) * 2017-07-10 2022-01-27 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof

Also Published As

Publication number Publication date
EP3941504A1 (en) 2022-01-26
US20220160842A1 (en) 2022-05-26
EP3941504A4 (en) 2022-12-07
JP2022525914A (ja) 2022-05-20
KR20210141667A (ko) 2021-11-23
CN114025782A (zh) 2022-02-08
AU2020244764A1 (en) 2021-10-14
IL286389A (en) 2021-10-31
WO2020198073A1 (en) 2020-10-01
BR112021018219A2 (pt) 2022-01-18
CA3134154A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
EP4331677A3 (en) Methods of treating feline coronavirus infections
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
ZA202304093B (en) Neuregulin-4 compounds and methods of use
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2018000240A (es) Metodos para tratar el vhc.
MX2019006768A (es) Peptidos antimicrobianos.
PH12018500202A1 (en) New effective aminoglycoside antibiotic for multidrug-resistant
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2021011469A (es) Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
WO2018220444A3 (en) COMPOSITIONS AND METHODS FOR TREATING DRY KERNATOCONJUNCTIVITIS SYNDROME BY ADMINISTERING A MACROLIDE ANTIBIOTIC
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
PH12020551620A1 (en) Compositions for preventing or treating dry eye